Project Grant HT94252310975
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$661K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
This $168,042 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports in vivo targeting research related to TFE3 dimerization partners in translocation renal cell carcinoma at Brigham & Women's Hospital Inc. in Boston, Massachusetts. The award will fund advanced biomedical research focused on developing innovative diagnostic and therapeutic approaches for this specific type of kidney cancer, which is...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
This $178,999 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is funding research conducted by Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to target TFE3 fusion proteins using proteolysis-targeting chimera (PROTAC) in translocation renal cell carcinoma (TRCC). The research aims to develop innovative diagnostic and therapeutic approaches...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $130,698 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support the development of the first targeted therapy for translocation renal cell carcinoma from August 15, 2022 to August 14, 2023. As the parent organization of the awardee, Partners Healthcare System Incorporated will oversee delivery of this innovative medical research effort to develop new...
This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
The Department of the Army Medical Command awarded $1,342,500 to Brigham & Women's Hospital Inc. under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "BIOMARKERS OF RESPONSE TO COMBINATION CABOZANTINIB + NIVOLUMAV IN ADVANCED RENAL CELL CARCINOMA" from July 1, 2022 to June 30, 2025. Under this Project Grant award, Brigham & Women's Hospital will conduct research to investigate biomarkers of response to combination...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $648,276 Project Grant under the Military Medical Research and Development program. The three-year award will fund research from September 2022 to September 2025 to target TFEB and TFE3 in renal tumorigenesis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care through innovative...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $169,372.00 to Brigham & Women's Hospital Inc. to support research on "ENGINEERING ANTAGOMIR NANODISCS TO REPROGRAM RCC-ASSOCIATED FIBROBLASTS". The award period runs from July 1, 2024 to June 30, 2026. The research aims to develop novel therapeutic approaches targeting renal cell carcinoma (RCC) by reprogramming the associated...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...